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The Role of Topoisomerase II Beta on Breakage and
Proximity of RUNX1 to Partner Alleles RUNX1T1
and EVI1
Kayleigh A. Smith,1 Ian G. Cowell,1 Yanming Zhang,2 Zbyslaw Sondka,1 and Caroline A. Austin1*
1Institute for Cellular and Molecular Biosciences,Newcastle University,Newcastle uponTyne,UK
2Departmentof Pathology,Northwestern University,Chicago,FL
Rearrangements involving the RUNX1 gene account for approximately 15% of balanced translocations in therapy-related
acute myeloid leukemia (t-AML) patients and are one of the most common genetic abnormalities observed in t-AML.
Drugs targeting the topoisomerase II (TOP2) enzyme are implicated in t-AML; however, the mechanism is not well under-
stood and to date a single RUNX1-RUNX1T1 t-AML breakpoint junction sequence has been published. Here we report an
additional five breakpoint junction sequences from t-AML patients with the RUNX1- RUNX1T1 translocation. Using a leu-
kemia cell line model, we show that TOP2 beta (TOP2B) is required for induction of RUNX1 chromosomal breaks by the
TOP2 poison etoposide and that, while TOP2 alpha (TOP2A) and TOP2B proteins are both present on RUNX1 and
RUNX1T1 chromatin, only the TOP2B enrichment reached significance following etoposide exposure at a region on
RUNX1 where translocations occur. Furthermore, we demonstrate that TOP2B influences the separation between RUNX1
and two translocation partners (RUNX1T1 and EVI) in the nucleus of lymphoid cells. Specifically, we identified a TOP2B-
dependent increase in the number of nuclei displaying juxtaposed RUNX1 and RUNX1T1 loci following etoposide
treatment. VC 2013 Wiley Periodicals, Inc.
INTRODUCTION
Therapy-related acute myeloid leukemia (t-
AML) is becoming an increasingly important late
effect following treatment for a primary malig-
nancy due to increased survival rates in patients.
At present, about 10% of all AML cases arise after
exposure to chemotherapy and/or radiation for a
primary malignancy or autoimmune disease
(Kayser et al., 2011). Topoisomerase II (TOP2)
poisons are used in many chemotherapy treatment
protocols and consist of intercalating agents, such
as mitoxantrone, and non-intercalating agents,
such as etoposide (Cowell and Austin, 2012). t-
AML following TOP2 poison containing chemo-
therapy regimens are associated with recurrent
balanced chromosome translocations involving the
RUNX1 (AML1), RUNX1T1 (ETO), MLL, PML,
and RARA loci.
TOP2 enzymes catalyze the inter-conversion of
different topological forms of DNA by passing one
double-stranded DNA duplex through a transient
enzyme-bridged break in a second DNA duplex
(Austin and Marsh, 1998). These enzyme-bridged
breaks, termed cleavage complexes, occur at low
steady-state levels in normal cells (Willmore et al.,
1998). Etoposide increases the steady-state levels
of cleavage complexes in the cell by preventing
religation of the transient TOP2 break, eventually
leading to apoptosis and cell death (Burden and
Osheroff, 1998). Human cells contain two TOP2
isozymes; alpha (TOP2A) and beta (TOP2B).
TOP2A is involved in chromosome condensation
and segregation and TOP2B has been implicated
in transcription (Lyu et al., 2006; Tiwari et al.,
2012), including modulation of transcription by
nuclear hormones, such as estradiol, androgen, and
retinoic acid (Ju et al., 2006; McNamara et al.,
2008; Perillo et al., 2008; Haffner et al., 2010; Wil-
liamson and Lees-Miller, 2011).
Approximately, 20–30% of therapy-related
hematologic disease cases contain balanced chro-
mosome translocations (Rowley and Olney, 2002).
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RUNX1 is a transcription factor involved in regu-
lating the differentiation of hematopoietic stem
cells into mature blood cells. About 15% of the
balanced translocations observed in therapy-
related acute leukemia (t-AL) involve RUNX1,
with the most common translocation partners
being RUNX1T1 (8q22) and EVI1 (3q26), observed
in 8% and 3% of cases respectively (Rowley and
Olney, 2002).
Certain chromatin structural elements are asso-
ciated with genomic breakpoint cluster regions in
leukemia, such as in vivo TOP2 cleavage sites,
DNase I hypersensitive sites, and scaffold attach-
ment regions (Strissel et al., 1998; Iarovaia et al.,
2004; Zhang and Rowley, 2006). DNase I hyper-
sensitive regions are a marker for gene regulatory
elements and have been found within break clus-
ter regions of some genes involved in t-AML, such
as MLL and RUNX1 (Strissel et al., 2000; Scharf
et al., 2006; Zhang and Rowley, 2006). Many
DNase I hypersensitive sites are associated with
scaffold attachment regions at gene boundaries or
within genes and some of these sites colocalize
with TOP2 sites at breakpoint regions in MLL,
MLLT3, AFF1, RUNX1, and RUNX1T1 (Aplan
et al., 1996; Strissel et al., 1998, 2000; Zhang et al.,
2002; Zhang and Rowley, 2006). The breakpoints
resulting in the RUNX1-RUNX1T1 (or RUNX1T1/
RUNX1) genomic fusion are located in intron 5 of
RUNX1 and predominately in intron 1 of the
RUNX1T1 gene (Supporting Information Figs. S1
and S2 and references therein). Although fewer
RUNX1-EVI1 (or EVI1-RUNX1) breakpoints have
been mapped at base pair level, several break-
points from patients with the RUNX1-EVI1/MDS1
genomic fusion have been located in intron 6 on
RUNX1 (Supporting Information Fig. S1 and refer-
ences therein). DNase I hypersensitive regions, in
vivo TOP2 cleavage sites, and scaffold attachment
regions have been detected within intron 5 of
RUNX1 and intron 1 of RUNX1T1 (Zhang et al.,
2002; Iarovaia et al., 2004; Zhang and Rowley,
2006). The location of the translocation sites
within introns is also constrained by the require-
ment to yield in frame fusion proteins.
The cytotoxicity of etoposide appears to be pre-
dominantly dependent on TOP2A (Errington
et al., 1999; Toyoda et al., 2008), whilst etoposide
genotoxicity determined by in vitro micronucleus
formation was TOP2B dependent (Cowell et al.,
2012). Indeed, in a mouse melanoma model,
etoposide-induced carcinogenesis involved
TOP2B rather than TOP2A (Azarova et al., 2007).
Furthermore, we have recently demonstrated that
the majority of etoposide-induced chromosomal
breaks in the MLL locus are dependent on
TOP2B (Cowell et al., 2012). Understanding the
role of TOP2B in etoposide-induced carcinogene-
sis may suggest ways to minimize bone marrow
genotoxicity in order to minimize t-AML. Here,
we report that etoposide-induced chromosomal
breaks in the RUNX1 locus are dependent on
TOP2B. In addition, we find that etoposide
increases the proportion of cells in which RUNX1
and RUNX1T1 loci are closely juxtaposed and that
this effect is TOP2B dependent. Unlike MLL,
where multiple t-AML patient breakpoints have
been published (Aplan et al., 1996; Atlas et al.,
1998; Strissel et al., 2000; Raffini et al., 2002;
Langer et al., 2003; Whitmarsh et al., 2003; Libura
et al., 2005; Felix et al., 2006; Cowell et al., 2012),
only one RUNX1-RUNX1T1 translocation break-
point has been mapped at base pair level from a t-
AML patient to date (Zhang et al., 2002). Without
this positional information it is difficult to
hypothesize on specific mechanisms involved in
therapy-related versus de novo RUNX1- RUNX1T1
leukemia cases (Shimizu et al., 1992; Xiao et al.,
2001; Zhang et al., 2002). Here, we report the
nucleotide positions of five additional t-AML
patient derived RUNX1 breakpoints.
MATERIALS AND METHODS
Cells
The human pre-B leukemia Nalm-6 and Nalm-
6TOP2B2/2 cell lines, described previously (Toyoda
et al., 2008), were maintained in RPMI medium
(Invitrogen, NY) supplemented with 10% (vol/vol)
fetal bovine serum (FBS) and penicillin/strepto-
mycin 1% (vol/vol) (PAA Yeovil, Somerset, UK).
Human myeloid leukemia KG1 cells were
obtained from European Collection of Cell Cul-
tures and were maintained in Iscove’s modified
Dulbecco minimal essential medium (IDMEM)
medium supplemented with 20% (vol/vol) FBS
and penicillin/streptomycin 1% (vol/vol) (PAA
Yeovil, Somerset, UK). All cell lines were incu-
bated at 37C with 5% CO2 in a humidified
atmosphere.
DNA-FISH
The interphase fluorescent in situ hybridization
(FISH) methodology was adapted to allow for con-
focal microscopy analysis as described previously
(Cowell et al., 2012). Lymphoid Nalm-6 or Nalm-
6TOP2B2/2 cells were used to enable the
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dependence on TOP2B to be determined, unlike
KG1 cells they do not contain six copies of
RUNX1T1. Metaphase DNA-FISH slides were
prepared by treating Nalm-6 or Nalm-6TOP2B2/2
cells with 0.2 ml colcemid (10 mg/ml) for 6 hr fol-
lowed by addition of etoposide/vehicle control at
37C for 72 h. Cells were incubated in 0.075M
KCl, pelleted at 1,0003g for 7 min, resuspended
drop-wise in methanol and acetic acid (3:1) fixative
and spotted onto poly-L-lysine coated slides
(VWR-U.K. Lutterworth, UK). Slides were proc-
essed as described for interphase FISH (Cowell
et al., 2012) and hybridized overnight at 37C
using the RUNX1 break-apart, RUNX1-RUNX1T1
fusion or RUNX1-RUNX1T1 dual fusion probe
(Cytocell, Cambridge, UK) or RUNX1-EVI1 dual
fusion probe (Kreatech, Amsterdam, The Nether-
lands). Slides were washed in 0.43SSC, 0.3%
NP40 at 736 1C for 2 min, washed in 23SSC,
0.1% NP40 for 1 min at room temperature, passed
through an ethanol series and air dried. Cells were
counterstained with DAPI and microscope analysis
was carried out using an Olympus IX81 motorized
microscope fitted with a grid confocal attachment
and Orca-AG camera (Hamamatsu Photonics,
Welwyn Garden City, UK). Confocal images were
collected using a 60 3 0.95 NA objective as
described previously (Cowell et al., 2012) and
image analysis was conducted using Volocity soft-
ware (Perkin-Elemer, Waltham, MA). At least 200
interphase nuclei and 60 metaphase spreads
(Felsher and Bishop, 1999) were scored per treat-
ment and experiments were carried out in tripli-
cate. Z-slice images, separated by 0.3 mm, from
confocal stacks taken from triplicate experiments
using the dual fusion probes were used to measure
3D distances between fusion partner alleles in 50
cells and the shortest distance was noted.
Chromatin Immunoprecipitation
ChIP was performed on KG1 myeloid cells
using the EZ-Magna ChIP kit protocol (Millipore,
Billerica, MA) as described previously (Cowell
et al., 2012) with the following modifications.
Chromatin was sonicated using a Bandelin Sono-
puls HD2070 sonicator at 12 3 15 sec per cycle at
20% power. Antibody concentrations and details of
primers used are detailed in the Supporting Infor-
mation Tables S1 and S2. All primers were synthe-
sized by Integrated DNA Technologies
(Interleuvenlaan, Belgium). Positive control ChIP
DNA (AcH3) was amplified using primers for the
GAPDH gene, supplied with the kit, and an anti-
green fluorescent protein (GFP) antibody was used
as a negative control. Data were analyzed using the
DCT method and experiments were repeated 3–4
times per antibody/primer. The following equation
was used to generate % input values for each anti-
body/treatment:
% input 5 100=2 Sample Ct2 INPUT Ct – Log2INPUT dilution foldð Þ½ :
At least three independent experiments were
carried out and unpaired t-tests were used to
determine significance (P< 0.05). Data are dis-
played as mean 6S.E.M.
RESULTS
Etoposide-Induced Chromosomal Breaks in
RUNX1 are TOP2B Dependent
Etoposide-induced chromosomal breaks in the
MLL locus are preferentially dependent on
TOP2B (Cowell et al., 2012). To investigate
whether TOP2B is required for etoposide-induced
chromosomal breaks in the RUNX1 locus, wild
type Nalm-6 cells containing both TOP2A and
TOP2B and Nalm-6 cells null for TOP2B (Nalm-
6TOP2B2/2) were treated with etoposide for 72 hr
to enable the cells to divide and to reveal chromo-
some breaks. Cells were analyzed by DNA-FISH
using a commercial RUNX1 break-apart probe
(Fig. 1A). A break in the chromosome was defined
as a split green-red signal separated by a distance
of at least two times the probe signal diameter
(Ventura et al., 2006) when using the RUNX1
break-apart probe (Fig. 1A). The data in Figure
1B show the percentage of nuclei scored as con-
taining chromosomal breaks in the RUNX1 locus
in the two cell lines, measured by DNA-FISH in
interphase cells. In the wild type, Nalm-6 cells not
exposed to etoposide 0.81% of the cells show
clearly separated DNA-FISH signals, indicative of
a chromosomal break. In the Nalm-6, wild type
cells following exposure to low dose etoposide
2.45% of the cells showed clearly separated DNA-
FISH signals, a 3.03-fold increase in the chromo-
somal breaks in the presence of etoposide
(P< 0.01). In the Nalm-6TOP2B2/2 cells that com-
pletely lack TOP2B the percentages were 0.83%
without etoposide and 0.98% with etoposide.
Three independent experiments were carried out.
In each experiment, 200 cells were scored for each
treatment. The statistical significance of the dif-
ferences was determined using unpaired t-tests.
The 3-fold increase in the percentage of nuclei
containing chromosomal breaks in the wild type
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Nalm-6 cells with etoposide was highly significant,
with a P value of <0.01. There was no significant
increase in the percentage of chromosomal breaks
in the Nalm-6TOP2B2/2 cells when treated with
etoposide. Both the wild type Nalm-6 and Nalm-
6TOP2B2/2 cells had comparable levels of breaks in
the absence of etoposide (0.81% and 0.83%,
respectively). Thus, etoposide induced a signifi-
cant number of RUNX1 chromosomal breaks in
Nalm-6 but not Nalm-6TOP2B2/2 cells. This indi-
cates a dependence on TOP2B for etoposide-
induced breaks in RUNX1.
Figures 1C and 1D show DNA-FISH with the
RUNX1 break-apart probe on metaphase spreads
from wild type Nalm-6 cells and Nalm-6TOP2B2/2
cells. More etoposide-induced RUNX1 rearrange-
ments were observed in metaphase spreads from
wild type cells than from Nalm-6TOP2B2/2 cells
completely lacking TOP2B, supporting the idea
that TOP2B plays a role in mediating etoposide
induced chromosomal breaks.
Sequenced Breakpoints from Patients with t-AML
Published to date, there are 99 sequenced
RUNX1 translocation breakpoints from patients
with the ETV6-RUNX1 translocation in acute lym-
phoblastic leukemia (ALL), which cluster within
introns 1 and 2 of RUNX1 (Supporting Information
Fig. S1 and Table S3 and references therein). In
addition, there are 40 sequenced RUNX1 translo-
cation breakpoints published from patients with
the RUNX1-RUNX1T1 translocation in de novo
AML and these cluster in intron 5 of RUNX1
(Supporting Information Fig. S1, Table S3, and
references therein). However, to our knowledge,
there is only one published sequenced breakpoint
from a t-AML patient with the RUNX1-RUNX1T1
translocation (Zhang et al., 2002) (Supporting
Information Table S3, P22). Here we report the
sequences of five further t-AML RUNX1-
RUNX1T1 translocation breakpoints (Fig. 2) iden-
tified previously (Zhang and Rowley, 2006) from
patients treated with TOP2 agents. All 40 reported
Figure 1. Etoposide-induced breaks in the RUNX1 gene in Nalm-6
and Nalm-6TOP2B-/- cells. Rearrangements in the RUNX1 gene in
response to etoposide treatment (100 nm Nalm-6; 150 nm Nalm-
6TOP2B2/2) for 72 hr. A: RUNX1 break-apart microscope images from
interphase DNA-FISH taken from Nalm-6 cells displaying a normal
RUNX1 gene configuration (n) or displaying a break in one of the
RUNX1 genes (br). The position of the RUNX1 break-apart probe is
depicted in the inset. B: Percentage of cells containing breaks in
RUNX1 using interphase DNA-FISH. Data are displayed as mean-
6 S.E.M from triplicate DNA-FISH experiments with 200 cells scored
per experiment. Unpaired t-tests were used to analyze significance
(P< 0.05) where **5 P< 0.01. C: Metaphase DNA-FISH microscope
images from Nalm-6 cells displaying a normal RUNX1 gene configura-
tion (n) or displaying a break in one of the RUNX1 genes (br). D: Per-
centage of cells containing breaks in RUNX1 where data is displayed as
the mean percentage from triplicate counts of at least 60 metaphase
spreads. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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de novo AML sites and six t-AML sites from
patients with the RUNX1-RUNX1T1 transloca-
tion are located within intron 5 of RUNX1 (Fig.
3A and Supporting Information Fig. S1) and
intron 1 of RUNX1T1 (Fig. 3B and Supporting
Information Fig. S2) (Zhang and Rowley, 2006).
These regions on RUNX1 and RUNX1T1 are
also associated with in vivo TOP2 cleavage sites,
DNase I hypersensitive regions, and scaffold
attachment regions (Iarovaia et al., 2004; Zhang
and Rowley, 2006). The six t-AML breakpoints
span 21 kb on the 260 kb RUNX1 gene and 4.5
kb on the 140 kb RUNX1T1 gene. Of the six
known t-AML RUNX1-RUNX1T1 sites, five are
within 1 kb of a DNase I hypersensitive site in
RUNX1T1, five are within 5 kb of a DNase I
hypersensitive site in RUNX1, and all six are
within 10 kb of a DNase I hypersensitive site in
RUNX1 and RUNX1T1 (Fig. 3; Supporting Infor-
mation Table S4).
Figure 2. Sequenced RUNX1-RUNX1T1 breakpoints from patients
with t-AML. Sequenced breakpoint junctions of translocations between
RUNX1 and RUNX1T1 in patients with therapy-related leukemia. The
genomic breakpoint junction sequence for Patient 1 is displayed as
Patient 22 in Supporting Information Table S3 (Zhang et al., 2002).
Underlined sequences represent the translocated sequence, double
underline indicates homologous regions at the breakpoint, and bold
font indicates non-template insertions at the junctions.
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TOP2B Occupancy Significantly Increases at t-
AMLTranslocation Sites in Response to Etoposide
To investigate TOP2B binding within chroma-
tin regions associated with translocations in t-
AML, TOP2 occupancy was determined at
selected regions of the RUNX1, RUNX1T1, and
EVI genes using ChIP and quantitative PCR
(QPCR). One region of interest in intron 5 of
RUNX1 is encompassed by ChIP primer pair
RUNX1D (Fig. 4 and Supporting Information Fig.
S1). It contains two t-AML patient derived break-
points and a TOP2 poison-induced breaksite from
a cell line model (Stanulla et al., 1997; Zhang
et al., 2002; Kantidze and Razin, 2007; Ottone
et al., 2009). One of the two patient sites in this
cluster is a RUNX1-RUNX1T1 breakpoint derived
from Patient 4 (Fig. 2); therefore, the correspond-
ing patient breakpoint on RUNX1T1 was chosen
for investigation (Fig. 4E and Supporting Informa-
tion Fig. S2, primer pair ETOA). Within exon 6
on RUNX1 there is a breakpoint observed in a
patient with t-AML characterized by the RUNX1-
MDS1-EVI1 translocation (Park et al., 2008).
Although the precise location of the break was not
reported, the corresponding EVI1 breakpoint was
selected for analysis (Supporting Information Fig.
S3A, primer pair EVI1B). For comparison, a region
outside of the BCR, near the internal transcription
start site of the RUNX1 gene, was also analyzed
(Fig. 4A and Supporting Information Fig. S1,
primer pair RUNX1B) along with a region of
RUNX1T1 that increases in TOP2B occupancy in
response to estradiol (unpublished data) (Fig. 4E,
primer pair ETOB). In addition, two further sites
from RUNX1 and one from RUNX1T1 and EVI,
which do not contain any published leukemia
breakpoints, were selected as control regions (Fig.
4 and Supporting Information Figs. S1–S3, primer
pairs RUNX1A, RUNX1C, ETOC, and EVI1A).
TOP2A and TOP2B ChIP data are expressed as
percentage input in Figure 4 and Supporting
Information Table S5 and as fold above negative
control (anti-GFP IgG) in Supporting Information
Figure S4 and Table S6.
Starting with site RUNX1A (800 kb upstream of
the RUNX1 TSS (Fig. 4A)), TOP2A and TOP2B
ChIP signals were above background, but treat-
ment of cells with etoposide did not increase
either (Figs. 4B and 4C and Supporting Informa-
tion Figs. S4B and S4C). At all other sites tested
in the RUNX1 gene, etoposide resulted in an
increase in TOP2B occupancy compared with
non-drug treated controls (Fig. 4B and Supporting
Information Fig. S4B). The increase in % input
was most significant (P< 0.01) for RUNX1D that
spans a t-AML site in intron 5 (Fig. 4B). Although
TOP2A occupancy was also consistently higher in
etoposide treated compared with untreated control
cells, this difference only reached significance at
one site, the promoter-proximal RUNX1B primer
Figure 3. Location of patient-derived t-AML breakpoints on RUNX1
and RUNX1T1. Patient (P) derived breakpoint locations on (A) RUNX1
and (B) RUNX1T1 therapy-related leukemia breakpoints (Zhang et al.,
2002; Ottone et al., 2009) and an etoposide-induced cleavage site (Sta-
nulla et al., 1997; Kantidze and Razin, 2007) are detailed. Patient break-
point sequences from this study are indicated with a blue diamond and
P1 refers to patient 22 in Supporting Information Table S3 (Zhang
et al., 2002). Transcription start site information and DNase I hyper-
sensitive sites (HS) are based on ENCODE data (Duke University,
North Carolina) from cell lines downloaded from the UCSC browser.
GM12878, lymphoblastic leukemia cell line; K562, myeloid leukemia cell
line; MCF7, breast cancer cell line. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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pair that coincides with the transcriptional start
site. With the RUNX1B primer pair both TOP2A
and TOP2B were significantly enriched (Fig. 4C).
Three sites in RUNX1T1 were sampled for
TOP2A and TOP2B occupancy. A small increase
in TOP2B binding was observed with the ETOA
and ETOC primer pairs in etoposide treated cells,
but this did not reach significance (Fig. 4F). Only
one region tested in RUNX1T1 significantly
increased in TOP2B occupancy in response to eto-
poside (Fig. 4F and Supporting Information Fig.
S4F, primer pair ETOB). None of the three sites
sampled for TOP2A occupancy on RUNX1T1
increased significantly in response to etoposide
treatment (Fig. 4G and Supporting Information
Fig. S4G). There was no significant difference in
TOP2A or TOP2B occupancy when comparing
untreated and etoposide treated cells at any site
tested in the EVI1 gene (Supporting Information
Figs. S3B and S3C).
Etoposide-Induced DSBs Correspond to Sites
Which Increase in TOP2B Occupancy on RUNX1
To investigate whether etoposide-induced dou-
ble strand breaks (DSBs) occur at sites in which
TOP2B is significantly enriched, gH2AX was used
as a surrogate marker for DSBs in the ChIP assay,
as has been previously described (Williamson and
Lees-Miller, 2011). The percentage of input data
is shown in Figure 4D and the fold increase over
the negative control is shown in Supporting Infor-
mation Figure S4D. gH2AX was significantly
enriched at the RUNX1C and RUNX1D primer
pairs (Fig. 4D). The enrichment for TOP2 at
these sites reached significance for TOP2B
Figure 4. Significant enrichment of TOP2B but not TOP2A at t-AML
site on RUNX1. Percentage input data from formaldehyde ChIP experi-
ments using KG1 cells6 etoposide (100 mM) for 1 hr or vehicle control.
A: QPCR primer positions on RUNX1, (B) TOP2B, (C) TOP2A occu-
pancy, and (D) gH2AX enrichment on RUNX1. E: QPCR primer posi-
tions on RUNX1T1, (F) TOP2B, (G) TOP2A occupancy, and (H) gH2AX
enrichment on RUNX1T1. RUNX1A—800 kb upstream from transcrip-
tion start site, RUNX1B—internal promoter, RUNX1C—intron 4,
RUNX1D—t-AML breakpoints (Stanulla et al., 1997; Kantidze and Razin,
2007; Ottone et al., 2009), ETOA—t-AML breakpoints, ETOB—estra-
diol site, ETOC—intron 3. Data is displayed as mean6 S.E.M and anti-
GFP antibody was used as a negative control. Unpaired t-tests were
used to analyze significance (P< 0.05) and experiments were performed
in triplicate. ****P< 0.0001, ***P< 0.001, **P< 0.01, *P< 0.05. Tran-
scription start sites are indicated as arrows and are based on ENCODE
DNase I hypersensitivity data from the UCSC browser.
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(Fig. 4B) but not for TOP2A (Fig. 4C). The
etoposide-induced enrichment of gH2AX (Fig.
4D and Supporting Information Fig. S4D) was
most significant at the t-AML RUNX1D primer
pair site and more significant than any other site
tested on the RUNX1 gene (Fig. 4B). However,
gH2AX was not significantly enriched at the
promoter-proximal RUNX1B site at which both
TOP2B and TOP2A occupancy increased in
response to etoposide (Figs. 4B and 4C, respec-
tively). These results suggest a significant
increase in DSBs on RUNX1, defined by gH2AX
enrichment, in etoposide treated cells at sites
where the increase in TOP2B occupancy reaches
significance but the TOP2A occupancy does not
reach significance. Etoposide-induced gH2AX
enrichment was also observed at sites tested on
the RUNX1T1 (Fig. 4H) and EVI1 genes (Sup-
porting Information Fig. S3D), however, these
increases did not reach significance.
Juxtaposition of RUNX1 and RUNX1T1 Alleles is
TOP2B Dependent
As TOP2B is required for most etoposide-
induced chromosome breaks in the RUNX1 gene,
as detected using a break-apart DNA-FISH probe
(Fig. 1B), we wished to investigate whether
etoposide-induced RUNX1-RUNX1T1 and/or
RUNX1-EVI1 fusions were reduced in frequency
in TOP2B null cells compared with wild type
cells. To this end we analyzed Nalm-6 and Nalm-
6TOP2B2/2 cells treated with IC50 concentrations of
etoposide (Toyoda et al., 2008) by interphase
FISH using commercially available RUNX1-
RUNX1T1 and RUNX1-EVI dual fusion probes. A
normal FISH pattern was defined as two green
and two red signals representing the two copies of
each gene (Fig. 5A, normal). A cell containing a
classical gene fusion as a result of reciprocal trans-
location would result in one of each normal allele,
i.e., one green and one red, and two overlapping
Figure 5. Distance between RUNX1 and partner alleles in Nalm-6
and Nalm-6TOP2B2/2 cells. Cells were treated with etoposide (100 nM
Nalm-6; 150 nM Nalm-6TOP2B2/2) for 72 hr and analyzed using RUNX1-
RUNX1T1 or RUNX1-EVI1 dual fusion probes. A: Microscope images
taken from Nalm-6 cells displaying a normal RUNX1-RUNX1T1 pattern
(n) or at least one set of overlapping RUNX1 and RUNX1T1 alleles (over/
l). B: Percentage of cells containing overlaps between RUNX1 and
RUNX1T1 (top) or RUNX1 and EVI1 (bottom). Data are displayed as
mean6 S.E.M from triplicate DNA-FISH with 200 cells scored per
experiment. Unpaired t-tests were used to analyze significance
(*P< 0.05). C: Microscope images comparing Nalm-6 cells containing at
least one set of RUNX1 and RUNX1T1 overlapping (over/l) alleles or
RUNX1 and RUNX1T1 alleles within 1 mm of one another. D: Percentage
of cells containing overlaps and/or alleles within 1 mm of one another
when analyzing the distance between RUNX1 and partner alleles. Values
displayed represent the mean percentage from 50 cells and counts were
performed in triplicate. Unpaired t-tests were used to analyze significance
(*P< 0.05) when comparing untreated and etoposide treated cells.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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red and green spots representing the dual fusion,
producing a yellow signal. In addition, one over-
lapping red and green signal with one normal red
and one normal green could result from closely
juxtaposed, but non-rearranged alleles rather than
gene fusions (Fig. 5A, over/l). Using the above cri-
teria, no RUNX1-RUNX1T1 or RUNX1-EVI1 dual
fusions were detected by interphase DNA-FISH
in either of the Nalm-6 cell lines tested, neither
before nor after etoposide treatment. Thus, we
conclude that the frequency with which these
events occur must be below that which can be
detected by this assay. Despite the lack of recipro-
cal translocation events, overlapping or closely jux-
taposed single RUNX1 and partner alleles were
observed in some cells (Fig. 5A). The frequency
with which RUNX1 and RUNX1T1 alleles were
juxtaposed in the nucleus was significantly higher
in etoposide treated Nalm-6 cells and this was
TOP2B dependent (Fig. 5B, top). There was a
small apparent etoposide-induced juxtaposition
between the RUNX1 and EVI1 alleles; however,
this did not reach significance and was seen in
both Nalm6 and Nalm6TOP2B2/2 cell lines sug-
gesting it was independent of TOP2B (Fig. 5B,
bottom). Metaphase FISH was performed to
exclude the possibility that the apparently juxta-
posed FISH signals resulted from non-reciprocal
RUNX1-RUNX1T1 rearrangements. However, no
fusion events were detected in at least 60 meta-
phase spreads of etoposide-treated Nalm-6 or
Nalm6TOP2B2/2 cell lines. Thus, we conclude the
single overlapping or closely positioned RUNX1/
RUNX1T1 signals reflect juxtaposition of the
respective loci in interphase cells.
To determine whether the observed TOP2B-
dependent, etoposide-induced juxtaposition of
RUNX1 and RUNX1T1 reflected a reduction in
average distance between RUNX1 and RUNX1T1
loci, the distance between the closest pairs of
RUNX1 and RUNX1T1 or RUNX1 and EVI1 alleles
was measured in the 3D nucleus of 50 cells.
Counts were performed in triplicate and the aver-
age distance between the closest RUNX1 and part-
ner genes was calculated. No significant difference
was observed in the average separation of the clos-
est pairs of RUNX1 and RUNX1T1 or RUNX1 and
EVI loci. However, when the distances measured
were divided into 1 mm intervals it became appa-
rent that etoposide had a significant effect on the
number of nuclei containing RUNX1 loci posi-
tioned within 1 mm of an RUNX1T1 locus (Figs.
5C and 5D and Supporting Information Fig. S5
and Table S7). A separation of <1 mm is significant
as this is the estimated radius of the volume that a
chromosome segment can explore by constrained
diffusion (Marshall et al., 1997; Chubb et al.,
2002). We considered this a cut-off for the separa-
tion of two genomic regions that are liable to come
into contact with each other over a timescale of
minutes to a few hours, as would be necessary for
recombination to occur subsequent to DSB induc-
tion. When considering RUNX1 and partner alleles
within 1 mm, treatment of cells with the IC50 dose
of etoposide resulted in a significant increase in
juxtaposed RUNX1-RUNX1T1 alleles in Nalm-6
cells but not in Nalm-6TOP2B2/2 cells (Fig. 5D).
An increase in RUNX1-EVI1 alleles within 1 mm
was also observed in Nalm-6 and Nalm-6TOP2B2/2
cells treated with the IC50 dose of etoposide (Fig.
5D); however, this increase did not reach
significance.
DISCUSSION
Exposure to TOP2 poisons for the treatment of
a primary malignancy is associated with t-AL with
translocations involving MLL at 11q23 (Aplan
et al., 1996; Atlas et al., 1998; Strissel et al., 1998;
2000; Raffini et al., 2002; Langer et al., 2003;
Whitmarsh et al., 2003; Libura et al., 2005; Felix
et al., 2006; Cowell et al., 2012), RUNX1 at 21q22
(Rowley and Olney, 2002; Godley and Larson,
2008), or the PML and RARA genes at 15q22 and
17q21, respectively (Mistry et al., 2005; Hasan
et al., 2008). Multiple translocation break junc-
tions involving the MLL (Meyer et al., 2009; Mar-
schalek, 2010) or PML (Hasan et al., 2008; 2010)
genes have been mapped at the base-pair level.
However, to our knowledge only a single RUNX1-
RUNX1T1 translocation break junction sequence
from a t-AML patient has been published to date
(Zhang et al., 2002). In this study, we report the
sequence information for an additional five t-AML
patient-derived breakpoints (Fig. 2). In addition to
these six RUNX1-RUNX1T1 cases, a RUNX1-
CBFA2T3 translocation was recently reported in a
patient with t-AML previously treated with the
TOP2 poison mitoxantrone (Ottone et al., 2009).
The RUNX1 translocation break site from this
translocation is within intron 5 of RUNX1 and is
only 540 bp away from the RUNX1-RUNX1T1
sequenced breakpoint from Patient 4 identified in
this study (Fig. 3). In addition, a region 150 bp
from the Patient 4 RUNX1 site has been shown to
be sensitive to teniposide-induced recombination
in a plasmid model system (Umanskaya et al.,
2006). This region at the 30-end of RUNX1 intron
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5 is of particular interest as the RUNX1 break site
from the RUNX1-CBFA2T3 translocation shares
90% homology with a cleavage “hotspot” in the
PML-RARA fusion gene in patients with therapy-
related acute promyelocytic leukemia after mitox-
antrone treatment (Mistry et al., 2005; Ottone
et al., 2009). DNA cleavage has also been mapped
to this region of RUNX1 intron 5 following treat-
ment of cultured cells with etoposide, although
this may reflect early higher-order apoptotic cleav-
age rather than direct etoposide-induced breaks
(Stanulla et al., 1997; Kantidze and Razin, 2007)
(Fig. 3). Although the RUNX1-RUNX1T1 t-AML
breakpoints reported in this study do not cluster
within a 1 kb “hotspot” region, as has been
observed in MLL (Atlas et al., 1998; Raffini et al.,
2002; Langer et al., 2003; Whitmarsh et al., 2003;
Libura et al., 2005; Cowell et al., 2012) or within 8
bp as has been found in PML (Mistry et al., 2005;
Hasan et al., 2008), all the breakpoints do reside
within intron 5 on RUNX1 and intron 1 on
RUNX1T1 (Fig. 3 and Supporting Information Fig.
S1, and references therein) and the 1 kb region
centered around patient site 4 does share certain
features with the cluster of t-AL translocation
break-sites observed in MLL. In both cases, the
region concerned is at the 30-end of an intron,
coincides with potentially apoptosis-related etopo-
side-induced cleavage in cultured cells (Strissel
et al., 1998; Mirault et al., 2006; Scharf et al.,
2006), and is associated with in vivo TOP2 cleav-
age sites, DNase I hypersensitivity, and a scaffold
attachment region (Strissel et al., 2000; Iarovaia
et al., 2004; Zhang and Rowley, 2006; Cowell
et al., 2012).
ChIP analysis allowed us to examine TOP2
occupancy at selected sites on the RUNX1 gene
(in introns 2, 4, and 5) in response to etoposide—
TOP2A and TOP2B protein levels increased at
these sites following etoposide treatment (Figs. 4B
and 4C and Supporting Information Figs. S4B and
S4C). The TOP2A increase only reached signifi-
cance with the RUNX1B primer pair which spans
the transcriptional start site which has more open
chromatin. The increase in TOP2B occupancy
reached significance at each of the sites tested in
the RUNX1 gene rather than a specific increase in
a t-AML associated region of intron 5 (Fig. 4B,
primer pair RUNX1D). This could be explained if
TOP2B binds and potentially cleaves multiple
areas on the RUNX1 gene, but only those at the t-
AML RUNX1 site gives the cell a survival advant-
age and are therefore observed in t-AML. The
intronic location of the t-AML site gives rise to a
fused gene that encodes an in-frame protein prod-
uct with altered properties that may confer a sur-
vival advantage to cells harboring this
translocation. Interestingly, only one of the regions
sampled on the RUNX1T1 gene significantly
increases in TOP2B occupancy in response to eto-
poside treatment (Fig. 4F, primer pair ETOB).
This site in RUNX1T1 is 670 bp from the E1 site
that is sensitive to teniposide-induced recombina-
tion (Umanskaya et al., 2006). This site is also
within a region in RUNX1T1 which has been shown
to contain a scaffold attachment region, a marker
often present at recombination hotspots (Iarovaia
et al., 2004). It is therefore of interest that TOP2B
occupancy (Fig. 4F) but not TOP2A occupancy
(Fig. 4G) increased significantly in this region in
response to etoposide. In addition, this significant
etoposide-induced TOP2B occupancy increase at a
single region sampled on RUNX1T1 is in contrast to
the etoposide-induced increase in TOP2B occu-
pancy observed at multiple sites tested on RUNX1
(Fig. 4B). Since the Q-PCR ChIP analysis only cov-
ers selected sites, it is also possible that other sites
may have higher occupancy levels. The gH2AX
levels rose at all the sites sampled after etoposide
treatment, but the increases did not reach signifi-
cance at all the sites sampled on RUNX1T1 and
EVI, suggesting the choice of sites to sample may
have been sub-optimal.
We have previously shown, using the gH2AX
assay as a marker for DSBs, that global genomic
DSBs are generated with equal efficiency in both
Nalm-6 cell lines wild type and null for TOP2B
(Cowell et al., 2012). We have also shown that
etoposide-induced chromosomal breaks in the
MLL locus are TOP2B dependent (Cowell et al.,
2012). In this study, using interphase DNA-FISH
with a RUNX1 break apart probe, we show that
etoposide-induced chromosomal breaks in the
RUNX1 locus are also TOP2B dependent (Fig.
1B). This supports our previously proposed model
that TOP2B-dependent breaks are involved in
generating the translocations that cause t-AML
(Cowell et al., 2012) (Supporting Information Fig.
S6).
Using interphase DNA-FISH with fusion
probes we demonstrate the effect of TOP2B on
the juxtaposition of RUNX1 and RUNX1T1 in
response to etoposide. The most common translo-
cation partners for RUNX1 in t-AML are
RUNX1T1 on 8q22 (56%) and, with a lesser fre-
quency, EVI1 on 3q26 (20%) (Rowley and Olney,
2002). Chromosomes 8 and 21 have been reported
to display a significantly enhanced co-localization
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in bone marrow cells of the myeloid lineage com-
pared with peripheral blood lymphocytes or bone
marrow cells of the lymphoid lineage (Manvelyan
et al., 2009). We investigated the effect of TOP2B
on the proximity of RUNX1 and RUNX1T1 alleles
in the nucleus in response to etoposide in lymph-
oid Nalm-6 cells wild type and null for TOP2B.
Etoposide treatment for 72 hr resulted in an appa-
rent increased frequency of juxtaposition of
RUNX1 and RUNX1T1 alleles and this phenom-
enon was dependent on TOP2B (Fig. 5B and Sup-
porting Information Fig. S5). We also investigated
the effect of TOP2B on the proximity of RUNX1
and EVI1 alleles as this translocation is observed
less frequently in t-AML compared with RUNX1-
RUNX1T1 (Zhang et al., 2002). Interestingly, the
apparent TOP2B-mediated juxtaposition between
alleles in etoposide treated Nalm-6 cell lines was
not observed when measuring the distance
between the RUNX1 and EVI1 alleles (Fig. 5B
and Supporting Information Fig. S5), a less fre-
quent translocation partner of RUNX1, inferring
that translocation frequency is relative to nuclear
position. We demonstrate a TOP2B-dependent
etoposide-induced juxtaposition of the RUNX1
and RUNX1T1 alleles in lymphoid Nalm-6 cell
lines. An etoposide-induced increase in proximity
of RUNX1 and RUNX1T1 alleles has previously
been reported in male fibroblast cells (Rubtsov
et al., 2008). However, this is the first indication
that TOP2B plays a role in the relative reposition-
ing of these alleles. Whether similar juxtapositions
are seen in cells of a myeloid lineage will require
further study.
We previously proposed a model suggesting
that TOP2B-dependent breaks within transcrip-
tion factories are misrepaired by non-homologous
end-joining to generate translocations involved in
t-AML (Supporting Information Fig. S6) (Cowell
et al., 2012). Support for this model comes from
the report highlighting the presence of non-
homologous end-joining components Ku and
DNA-PKCS at the t-AML breakpoint in RUNX1
(Kantidze and Razin, 2007). The QPCR ChIP
work we report here demonstrates an enrichment
of TOP2B protein but not TOP2A at sites of
translocations in t-AML patients. This coupled
with DNA-FISH data showing TOP2B depend-
ence for etoposide-induced chromosomal breaks
in RUNX1 and a TOP2B dependent juxtaposition
of RUNX1 and RUNX1T1 are all consistent with a
role for TOP2B in producing the DNA break
needed to generate a translocation in t-AML, as
suggested by our model.
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